文献速递MDS 与骨髓增殖性肿瘤

利用循环肿瘤DNA对骨髓增生异常综合征进行分子疾病监测

Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes.
PubMed 文献 · Blood · 2017-01-26

该研究通过分析75份连续骨髓与配对血浆样本,证明游离循环肿瘤DNA(ctDNA)在反映骨髓增生异常综合征(MDS)恶性克隆基因组异质性方面与骨髓活检直接可比,且连续监测ctDNA可同时追踪突变和核型异常并预见治疗失败,提示ctDNA可作为MDS的微创分子疾病监测策略。

要点

  • 连续监测ctDNA可同时追踪MDS的基因突变与核型异常。
  • ctDNA监测能够预见MDS治疗失败。
  • ctDNA在反映MDS恶性克隆基因组异质性方面与骨髓活检直接可比。

核心结论

  • 游离循环肿瘤DNA(ctDNA)在代表MDS恶性克隆基因组异质性方面与骨髓活检直接可比。
  • 连续监测ctDNA可同时追踪治疗过程中的突变和核型异常,并能预见治疗失败。
  • 这些数据突显了ctDNA作为MDS微创分子疾病监测策略的作用。

研究设计与样本

  • 研究分析了连续骨髓与配对血浆样本(n=75),比较ctDNA与骨髓活检在反映MDS恶性克隆基因组异质性方面的一致性。

主要发现

  • 通过分析连续骨髓和配对血浆样本(n=75),证明游离循环肿瘤DNA(ctDNA)在代表MDS恶性克隆基因组异质性方面与骨髓活检直接可比。
  • 连续监测ctDNA可在整个治疗过程中同时追踪突变和核型异常,并能够预见治疗失败。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The diagnosis and monitoring of myelodysplastic syndromes (MDSs) are highly reliant on bone marrow morphology, which is associated with substantial interobserver variability. Although azacitidine is the mainstay of treatment in MDS, only half of all patients respond. Therefore, there is an urgent need for improved modalities for the diagnosis and monitoring of MDSs. The majority of MDS patients have either clonal somatic karyotypic abnormalities and/or gene mutations that aid in the diagnosis and can be used to monitor treatment response. Circulating cell-free DNA is primarily derived from hematopoietic cells, and we surmised that the malignant MDS genome would be a major contributor to cell-free DNA levels in MDS patients as a result of ineffective hematopoiesis. Through analysis of serial bone marrow and matched plasma samples (n = 75), we demonstrate that cell-free circulating tumor DNA (ctDNA) is directly comparable to bone marrow biopsy in representing the genomic heterogeneity of malignant clones in MDS. Remarkably, we demonstrate that serial monitoring of ctDNA allows concurrent tracking of both mutations and karyotypic abnormalities throughout therapy and is able to anticipate treatment failure. These data highlight the role of ctDNA as a minimally invasive molecular disease monitoring strategy in MDS.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Yeh P, Dickinson M, Ftouni S, et al. Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes. Blood. 2017. PMID: 28126926. doi:10.1182/blood-2016-09-740308

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。